155 related articles for article (PubMed ID: 17331556)
1. The role of N-glycosylation sites on the CXCR4 receptor for CXCL-12 binding and signaling and X4 HIV-1 viral infectivity.
Huskens D; Princen K; Schreiber M; Schols D
Virology; 2007 Jul; 363(2):280-7. PubMed ID: 17331556
[TBL] [Abstract][Full Text] [Related]
2. X4 HIV-1 induces neuroblastoma cell death by interference with CXCL12/CXCR4 interaction.
Hatse S; Bridger G; de Clercq E; Schols D
Cell Mol Biol (Noisy-le-grand); 2003; 49 Online Pub():OL443-52. PubMed ID: 14995074
[TBL] [Abstract][Full Text] [Related]
3. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.
Donzella GA; Schols D; Lin SW; Esté JA; Nagashima KA; Maddon PJ; Allaway GP; Sakmar TP; Henson G; De Clercq E; Moore JP
Nat Med; 1998 Jan; 4(1):72-7. PubMed ID: 9427609
[TBL] [Abstract][Full Text] [Related]
4. CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.
Klasse PJ; Rosenkilde MM; Signoret N; Pelchen-Matthews A; Schwartz TW; Marsh M
J Virol; 1999 Sep; 73(9):7453-66. PubMed ID: 10438835
[TBL] [Abstract][Full Text] [Related]
5. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100.
Hatse S; Princen K; Gerlach LO; Bridger G; Henson G; De Clercq E; Schwartz TW; Schols D
Mol Pharmacol; 2001 Jul; 60(1):164-73. PubMed ID: 11408611
[TBL] [Abstract][Full Text] [Related]
6. Identification of residues of CXCR4 critical for human immunodeficiency virus coreceptor and chemokine receptor activities.
Brelot A; Heveker N; Montes M; Alizon M
J Biol Chem; 2000 Aug; 275(31):23736-44. PubMed ID: 10825158
[TBL] [Abstract][Full Text] [Related]
7. AMD3465, a monomacrocyclic CXCR4 antagonist and potent HIV entry inhibitor.
Hatse S; Princen K; De Clercq E; Rosenkilde MM; Schwartz TW; Hernandez-Abad PE; Skerlj RT; Bridger GJ; Schols D
Biochem Pharmacol; 2005 Sep; 70(5):752-61. PubMed ID: 16011832
[TBL] [Abstract][Full Text] [Related]
8. Unique ligand binding sites on CXCR4 probed by a chemical biology approach: implications for the design of selective human immunodeficiency virus type 1 inhibitors.
Choi WT; Tian S; Dong CZ; Kumar S; Liu D; Madani N; An J; Sodroski JG; Huang Z
J Virol; 2005 Dec; 79(24):15398-404. PubMed ID: 16306611
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.
Princen K; Hatse S; Vermeire K; Aquaro S; De Clercq E; Gerlach LO; Rosenkilde M; Schwartz TW; Skerlj R; Bridger G; Schols D
J Virol; 2004 Dec; 78(23):12996-3006. PubMed ID: 15542651
[TBL] [Abstract][Full Text] [Related]
10. Nonproductive human immunodeficiency virus type 1 infection of human fetal astrocytes: independence from CD4 and major chemokine receptors.
Sabri F; Tresoldi E; Di Stefano M; Polo S; Monaco MC; Verani A; Fiore JR; Lusso P; Major E; Chiodi F; Scarlatti G
Virology; 1999 Nov; 264(2):370-84. PubMed ID: 10562499
[TBL] [Abstract][Full Text] [Related]
11. Infection of cells expressing CXCR4 mutants lacking N-glycosylation at the N-terminal extracellular domain is enhanced for R5X4-dualtropic human immunodeficiency virus type-1.
Thordsen I; Polzer S; Schreiber M
BMC Infect Dis; 2002 Dec; 2():31. PubMed ID: 12489987
[TBL] [Abstract][Full Text] [Related]
12. N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins.
Wang J; Babcock GJ; Choe H; Farzan M; Sodroski J; Gabuzda D
Virology; 2004 Jun; 324(1):140-50. PubMed ID: 15183061
[TBL] [Abstract][Full Text] [Related]
13. Mutations at the CXCR4 interaction sites for AMD3100 influence anti-CXCR4 antibody binding and HIV-1 entry.
Hatse S; Princen K; Vermeire K; Gerlach LO; Rosenkilde MM; Schwartz TW; Bridger G; De Clercq E; Schols D
FEBS Lett; 2003 Jul; 546(2-3):300-6. PubMed ID: 12832058
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationship of neomycin, paromomycin, and neamine-arginine conjugates, targeting HIV-1 gp120-CXCR4 binding step.
Borkow G; Vijayabaskar V; Lara HH; Kalinkovich A; Lapidot A
Antiviral Res; 2003 Nov; 60(3):181-92. PubMed ID: 14638394
[TBL] [Abstract][Full Text] [Related]
15. Increase of R5 HIV-1 infection and CCR5 expression in T cells treated with high concentrations of CXCR4 antagonists and SDF-1.
Gotoh K; Yoshimori M; Kanbara K; Tamamura H; Kanamoto T; Mochizuki K; Fujii N; Nakashima H
J Infect Chemother; 2001 Mar; 7(1):28-36. PubMed ID: 11406754
[TBL] [Abstract][Full Text] [Related]
16. The antiviral activity of the CXCR4 antagonist AMD3100 is independent of the cytokine-induced CXCR4/HIV coreceptor expression level.
Princen K; Hatse S; Vermeire K; Bridger GJ; Skerlj RT; De Clercq E; Schols D
AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1135-9. PubMed ID: 14709250
[TBL] [Abstract][Full Text] [Related]
17. Cyclic zinc-dithiocarbamate-S,S'-dioxide blocks CXCR4-mediated HIV-1 infection.
Takamune N; Misumi S; Shoji S
Biochem Biophys Res Commun; 2000 Jun; 272(2):351-6. PubMed ID: 10833417
[TBL] [Abstract][Full Text] [Related]
18. A peptide derived from bee venom-secreted phospholipase A2 inhibits replication of T-cell tropic HIV-1 strains via interaction with the CXCR4 chemokine receptor.
Fenard D; Lambeau G; Maurin T; Lefebvre JC; Doglio A
Mol Pharmacol; 2001 Aug; 60(2):341-7. PubMed ID: 11455021
[TBL] [Abstract][Full Text] [Related]
19. Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.
Sironi F; Malnati M; Mongelli N; Cozzi P; Guzzo C; Ghezzi S; Martínez-Romero C; García-Sastre A; Lusso P; Jabes D; Biswas P
J Transl Med; 2015 Apr; 13():107. PubMed ID: 25888743
[TBL] [Abstract][Full Text] [Related]
20. NeoR6 inhibits HIV-1-CXCR4 interaction without affecting CXCL12 chemotaxis activity.
Lapidot A; Peled A; Berchanski A; Pal B; Kollet O; Lapidot T; Borkow G
Biochim Biophys Acta; 2008 Jun; 1780(6):914-20. PubMed ID: 18410746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
